BlackRock, Inc. Reports 5.9% Ownership in Maravai Lifesciences Holdings, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, reporting a 5.9% ownership in Maravai Lifesciences Holdings, Inc. as of September 30, 2025. The filing indicates that BlackRock beneficially owns 8,580,553 shares of common stock, with sole voting power over 8,375,467 shares and sole dispositive power over all 8,580,553 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.